OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company

OmniAb signs up to $370M licensing deal with Eli Lilly for ion channel program (LLY:NYSE)

OmniAb partners with Eli Lilly on a new ion channel program, earning upfront cash plus up to $370M milestones and royalties.

OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company

OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of

OmniAb and Eli Lilly collaborate on new ion channel program - BioTuesdays

OmniAb (NASDAQ: OABI) has announced a global collaboration and license agreement with Eli Lilly and Company (NYSE: LLY) for a new ion channel program, leveraging OmniAb’s technology platform and expertise in ion channel discovery and screening. Under the terms of the agreement, OmniAb will receive an upfront payment and is eligible to receive up to $370 million in research, development, and commercial milestone payments, as well as tiered royalt…

Lilly to pay up to $370M for OmniAb collab; Slate, Fulcrum forge reverse merger

🤝 OmniAb’s Lilly pact: The California drug discovery shop has an ion channel collaboration and licensing agreement in place with the GLP-1 giant. Eli Lilly will pay up to $370 million ...